NKTR - Nektar Therapeutics
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
NKTR price evolution
NKTR
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $35.28 | $64.92 | $50.73 | $76.95 |
| Short term investments | $268.34 | $307.74 | $358.7 | $379.87 |
| Net receivables | $1.21 | $2.2 | $1.33 | $3 |
| Inventory | $16.1 | $15.13 | $20.69 | $20.23 |
| Total current assets | $330.7 | $399.02 | $441.06 | $491.07 |
| Long term investments | $25.82 | |||
| Property, plant & equipment | $36.86 | $38.7 | $51.57 | $69.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $67.33 | $43.22 | $53.22 | $70.68 |
| Total investments | $294.16 | $307.74 | $358.7 | $379.87 |
| Total assets | $398.03 | $442.24 | $494.28 | $561.74 |
| Current liabilities | ||||
| Accounts payable | $9.85 | $3.29 | $2.62 | $3.7 |
| Deferred revenue | ||||
| Short long term debt | $19.26 | $19.09 | $18.93 | $18.77 |
| Total current liabilities | $51.27 | $52.11 | $50.69 | $59.88 |
| Long term debt | $98.52 | $102.19 | $105.82 | $109.39 |
| Total noncurrent liabilities | $215.78 | $230.76 | $246.63 | $261 |
| Total debt | $117.78 | $121.29 | $124.75 | $128.16 |
| Total liabilities | $267.05 | $282.88 | $297.32 | $320.88 |
| Shareholders' equity | ||||
| Retained earnings | -$3477.25 | -$3435.17 | -$3389.33 | -$3338.21 |
| Other shareholder equity | $0.08 | -$6.35 | -$6.45 | -$5.68 |
| Total shareholder equity | $130.99 | $159.37 | $196.96 | $240.87 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $35.28 | $88.23 | $25.22 | $198.96 |
| Short term investments | $268.34 | $416.75 | $708.74 | $862.94 |
| Net receivables | $1.21 | $5.98 | $22.49 | $38.89 |
| Inventory | $16.1 | $19.2 | $15.8 | $15.29 |
| Total current assets | $330.7 | $545.97 | $795.58 | $1138.01 |
| Long term investments | $25.82 | $64.83 | $136.66 | |
| Property, plant & equipment | $36.86 | $85.89 | $177.53 | $186.14 |
| Goodwill & intangible assets | $76.5 | $76.5 | $76.5 | |
| Total noncurrent assets | $67.33 | $164.63 | $321.61 | $400.76 |
| Total investments | $294.16 | $416.75 | $773.57 | $999.6 |
| Total assets | $398.03 | $710.6 | $1117.19 | $1538.77 |
| Current liabilities | ||||
| Accounts payable | $9.85 | $12.98 | $9.75 | $22.14 |
| Deferred revenue | $2.56 | |||
| Short long term debt | $19.26 | $18.67 | $17.44 | $13.91 |
| Total current liabilities | $51.27 | $68.2 | $85.2 | $115.78 |
| Long term debt | $98.52 | $112.83 | $125.74 | $136.37 |
| Total noncurrent liabilities | $215.78 | $275.76 | $352.48 | $345.69 |
| Total debt | $117.78 | $131.5 | $143.18 | $150.29 |
| Total liabilities | $267.05 | $343.96 | $437.68 | $461.47 |
| Shareholders' equity | ||||
| Retained earnings | -$3477.25 | -$3201.19 | -$2832.99 | -$2309.16 |
| Other shareholder equity | $0.08 | -$6.91 | -$4.16 | -$2.29 |
| Total shareholder equity | $130.99 | $366.64 | $679.51 | $1077.3 |
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $23.89 | $20.5 | ||
| Cost of revenue | $7.28 | $6.99 | ||
| Gross Profit | $16.6 | $13.51 | ||
| Operating activities | ||||
| Research & development | $29.94 | $29.68 | ||
| Selling, general & administrative | $17.32 | $17.87 | ||
| Total operating expenses | $50.11 | $64.1 | ||
| Operating income | -$33.51 | -$50.6 | ||
| Income from continuing operations | ||||
| EBIT | -$35.24 | -$45.02 | ||
| Income tax expense | -$0.03 | -$0.05 | ||
| Interest expense | $6.87 | $6.15 | ||
| Net income | ||||
| Net income | -$42.08 | -$51.12 | ||
| Income (for common shares) | -$42.08 | -$51.12 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $90.12 | $92.06 | $101.91 | $152.91 |
| Cost of revenue | $33.77 | $21.64 | $24.9 | $19.48 |
| Gross Profit | $56.35 | $70.42 | $77.01 | $133.44 |
| Operating activities | ||||
| Research & development | $114.16 | $218.32 | $400.27 | $408.68 |
| Selling, general & administrative | $77.42 | $92.33 | $122.84 | $104.68 |
| Total operating expenses | $320.04 | $446.59 | $523.11 | $558.55 |
| Operating income | -$263.68 | -$376.17 | -$446.1 | -$425.11 |
| Income from continuing operations | ||||
| EBIT | -$250.92 | -$336.07 | -$475.97 | -$437.1 |
| Income tax expense | -$0.2 | $3.21 | $0.56 | $0.49 |
| Interest expense | $25.33 | $28.91 | $47.31 | $6.85 |
| Net income | ||||
| Net income | -$276.06 | -$368.2 | -$523.84 | -$444.44 |
| Income (for common shares) | -$276.06 | -$368.2 | -$523.84 | -$444.44 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$42.08 | -$45.84 | -$51.12 | -$137.02 |
| Operating activities | ||||
| Depreciation | $1.65 | $1.7 | $2.17 | $2.3 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.25 | $8.15 | $7.97 | $10.02 |
| Total cash flows from operations | -$47.05 | -$42.12 | -$51.52 | -$51.91 |
| Investing activities | ||||
| Capital expenditures | -$0.24 | $1.21 | -$0.16 | -$0.43 |
| Investments | $17.62 | $55.2 | $25.33 | $41.03 |
| Total cash flows from investing | $17.38 | $56.41 | $25.17 | $40.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0.02 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.01 | $0.02 | ||
| Effect of exchange rate | $0.01 | -$0.1 | $0.11 | $0.04 |
| Change in cash and equivalents | -$29.64 | $14.19 | -$26.23 | -$11.27 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$276.06 | -$368.2 | -$523.84 | -$444.44 |
| Operating activities | ||||
| Depreciation | $7.82 | $13.03 | $14.15 | $14.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $33.39 | $57.32 | $94.67 | $94.26 |
| Total cash flows from operations | -$192.61 | -$304.01 | -$412.66 | -$313.29 |
| Investing activities | ||||
| Capital expenditures | $0.38 | $7.52 | -$14.99 | -$7.26 |
| Investments | $139.18 | $358.31 | $217.77 | $503.47 |
| Total cash flows from investing | $139.56 | $365.83 | $202.78 | $496.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.76 | $33.24 | $23.4 |
| Net borrowings | -$250 | |||
| Total cash flows from financing | $0.03 | $1.51 | $36.24 | -$80.35 |
| Effect of exchange rate | $0.06 | -$0.33 | -$0.09 | $0.02 |
| Change in cash and equivalents | -$52.95 | $63.01 | -$173.74 | $102.59 |
News
Fundamentals
| Market cap | $252.63M |
|---|---|
| Enterprise value | $335.13M |
| Shares outstanding | 191.38M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 8.45% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.93 |
| Book/Share | 0.68 |
| Cash/Share | 0.18 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 2.04 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.45 |
| Quick ratio | 6.14 |